Ladenburg analyst Aydin Huseynov downgraded Quoin Pharmaceuticals to Neutral from Buy.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on QNRX:
- Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results
- Quoin Pharmaceuticals reports Q4 earnings per ADS (41c), consensus (62c)
- Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET
- Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
- Quoin Pharmaceuticals 4.95M ADS secondary priced at $1.00